Floatz logo

Cynk-001

Leukemia, Myeloid

Celularity IncorporatedCell therapyPhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Leukemia, Myeloid cohort.

Asset / SponsorPhaseRating
Fludarabine
M.D. Anderson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Actinium Pharmaceuticals
Phase 2/3BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 3BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 2BB
Rapamycin
Masonic Cancer Center, University of Minnesota
Phase 2BB

View all 50 →

Same molecule, other indications

Cynk-001 is also rated in:

giant cell glioblastomaDormant
C
Indicative ·
37 / 100
View asset →
glioblastomaDormant
C
Indicative ·
37 / 100
View asset →
monoclonal paraproteinemia diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →